Skip to main navigation
Manage consent
Kronos Bio logoKronos Bio logo

Investor Relations

  • Company
    • About Us
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
    • Our Stories
    • Policies & Notices
    • Contact Page
  • Science & Pipeline
    • Discovery
    • Pipeline
    • Publications
  • Clinical Trials
  • Investors & Media
    • Overview
    • Press Releases
    • Events & Presentations
    • Stock Information
      • Stock Quote & Chart
      • Analyst Coverage
    • Corporate Governance
    • SEC Filings
    • Financials & Filings
      • Quarterly Results
    • IR Resources
      • Investor FAQs
      • Email Alerts
      • Investor & Media Contact
  • Careers
Menu

Investor Relations - Top Nav

  • Company
    • About Us
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
    • Our Stories
    • Policies & Notices
    • Contact Page
  • Science & Pipeline
    • Discovery
    • Pipeline
    • Publications
  • Clinical Trials
  • Investors & Media
    • Overview
    • Press Releases
    • Events & Presentations
    • Stock Information
      • Stock Quote & Chart
      • Analyst Coverage
    • Corporate Governance
    • SEC Filings
    • Financials & Filings
      • Quarterly Results
    • IR Resources
      • Investor FAQs
      • Email Alerts
      • Investor & Media Contact
  • Careers

Press Releases

Jan 09, 2023
Kronos Bio Announces Discovery Collaboration with Genentech to Advance Novel Therapies Against Transcriptional Targets in Oncology

Contact

Headquarters

Kronos Bio, Inc.
1300 So. El Camino Real
Suite 400
San Mateo, CA 94402
+1 (650) 781-5200

Research Facility

Kronos Bio, Inc.
301 Binney Street
2nd Floor East
Cambridge, MA 02142

PARTNERING INQUIRIES

bd@kronosbio.com

MEDIA INQUIRIES

media@kronosbio.com

INVESTOR INQUIRIES

investor@kronosbio.com

EMPLOYMENT INQUIRIES

careers@kronosbio.com

 

  • Linkedin
UK and EU Privacy Contacts
Policies & Notices

© 2022 All rights reserved.

TOP